INT298821

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.77
First Reported 2009
Last Reported 2009
Negated 1
Speculated 1
Reported most in Body
Documents 1
Total Number 53
Disease Relevance 32.53
Pain Relevance 2.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
adipocytes 8
liver 5
afferent neurons 5
3T3-L1 2
visceral 1
TUSC5 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 1272 99.20 Very High Very High Very High
Potency 106 96.56 Very High Very High Very High
Central nervous system 53 95.40 Very High Very High Very High
dexamethasone 53 91.84 High High
Peripheral nervous system 53 85.40 High High
Immobilon 53 56.48 Quite High
anesthesia 53 19.84 Low Low
lidocaine 53 19.40 Low Low
Disease Link Frequency Relevance Heat
Obesity 7314 100.00 Very High Very High Very High
Cancer 265 100.00 Very High Very High Very High
Repression 53 99.92 Very High Very High Very High
Diabetes Mellitus 530 99.56 Very High Very High Very High
Liver Cancer 159 94.56 High High
Targeted Disruption 53 94.48 High High
Disease 53 94.20 High High
Lung Cancer 53 85.16 High High
Retinoblastoma 53 65.96 Quite High
Insulin Resistance 53 46.68 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
1 overexpression on expression of Tusc5, samples were used from a previously published study in which PPAR?
Gene_expression (expression) of Tusc5
1) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.32 Pain Relevance 0
The lack of effect of PIO in triggering WAT Tusc5 expression in our human cohorts (in contrast to the robust increase in murine adipocytes) might point to potential species-specific differences in the Tusc5-PPAR?
Gene_expression (expression) of WAT Tusc5 in adipocytes associated with obesity
2) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.73 Pain Relevance 0.03
For microarray studies comparing Tusc5 WAT gene expression in type 2 diabetics treated with TZDs, paired t-tests were employed to compare fluorescence signal values pre- versus posttreatment.
Gene_expression (expression) of Tusc5 WAT gene associated with diabetes mellitus and obesity
3) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.83 Pain Relevance 0.08
2 on hepatic expression of Tusc5, archived samples were used from a previously published experiment in which C57BL/6 mice were i.v. treated with adenovirus preparations containing either murine PPAR?
Gene_expression (expression) of Tusc5
4) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.26 Pain Relevance 0
The basis for the unique tissue specificity of Tusc5 expression remains unexplored, but the robust activation of Tusc5 gene expression by PPAR?
Gene_expression (expression) of Tusc5 gene
5) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.53 Pain Relevance 0.05
A significant depot effect (P = .05) and depot × obesity interaction (P < .001) was observed, explained by the significantly lower Tusc5 expression in the visceral versus SC WAT of non-obese subjects that was not observed in obese persons (Figure 5).


Gene_expression (expression) of Tusc5 in visceral associated with obesity
6) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 1.60 Pain Relevance 0.06
agonist GW1929 [6] or the less potent thiazolidinedione (TZD) agonist troglitazone in order to generate a dose-response relationship of Tusc5 expression (n = 4/per dose); controls were grown in media containing dimethyl sulfoxide vehicle (DMSO; 0.1% by vol.).
Gene_expression (expression) of Tusc5 associated with agonist
7) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.14 Pain Relevance 0.19
However, in subjects treated for the same period of time but using rosiglitazone, there was a trend for increased Tusc5 mRNA expression: 3132 ± 351 versus 4286 ± 433 (P = .07).

3.2.

Gene_expression (expression) of Tusc5 mRNA
8) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.54 Pain Relevance 0.04
The basis for the unique tissue specificity of Tusc5 expression remains unexplored, but the robust activation of Tusc5 gene expression by PPAR?
Gene_expression (expression) of Tusc5
9) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.48 Pain Relevance 0.05
Finally, considering that samples were obtained only at a single late timepoint following pioglitazone treatment, it is possible that WAT Tusc5 expression was actively regulated during the more dynamic phase of early TZD treatment.
Gene_expression (expression) of WAT Tusc5 associated with obesity
10) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.56 Pain Relevance 0
We reasoned that Tusc5 expression, like that of the classic PPAR?
Gene_expression (expression) of Tusc5
11) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.39 Pain Relevance 0
Expression of Tusc5 mRNA in Obese Human WATThe effects of obesity and differences between adipose depots with respect to Tusc5 mRNA abundance were analyzed using archived human WAT samples from nonobese (n = 10) and obese (n = 12) subjects.
Spec (analyzed) Gene_expression (Expression) of Tusc5 mRNA associated with obesity
12) Confidence 0.77 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.54 Pain Relevance 0
Expression of Tusc5 mRNA in Obese Human WATThe effects of obesity and differences between adipose depots with respect to Tusc5 mRNA abundance were analyzed using archived human WAT samples from nonobese (n = 10) and obese (n = 12) subjects.
Gene_expression (abundance) of Tusc5 mRNA associated with obesity
13) Confidence 0.67 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.55 Pain Relevance 0
-TUSC5 interactions, Tusc5 mRNA levels were compared in archived human WAT biopsy samples before and after treatment with the PPAR?
Gene_expression (levels) of Tusc5 mRNA associated with obesity
14) Confidence 0.67 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.70 Pain Relevance 0.08
target gene, but a relationship between Tusc5, obesity, and pharmacological actions of PPAR?
Gene_expression (obesity) of Tusc5 associated with obesity
15) Confidence 0.67 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.70 Pain Relevance 0.16
Notable was the large variability in Tusc5 gene expression changes over time both in the placebo- and pioglitizone-treated subjects.
Gene_expression (expression) of Tusc5 gene
16) Confidence 0.67 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.54 Pain Relevance 0.04
The lack of effect of PIO in triggering WAT Tusc5 expression in our human cohorts (in contrast to the robust increase in murine adipocytes) might point to potential species-specific differences in the Tusc5-PPAR?
Gene_expression (differences) of Tusc5 in adipocytes associated with obesity
17) Confidence 0.67 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.74 Pain Relevance 0.03
Unlike positive control human WAT cDNA analyzed in parallel, Tusc5 mRNA was nondetectable in HepG2 cells under all conditions (transcripts for leptin and AdipoQ/adiponectin were also not detected).
Gene_expression (nondetectable) of Tusc5 mRNA associated with obesity
18) Confidence 0.67 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.38 Pain Relevance 0.07
Using a subset of patients for whom archived WAT was available for measurement of Tusc5 protein abundance, consistent with the mRNA results there was large person-to-person variability in Tusc5 expression and no effect of pioglitazone treatment on Tusc5 protein levels when comparing pre- and post-treatment WAT (Supplementary Figure 2).
Gene_expression (expression) of Tusc5 associated with obesity
19) Confidence 0.67 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.58 Pain Relevance 0.03
Microarray gene expression results from a separate cohort of type 2 diabetics treated with pioglitizone for 12 weeks also showed no increased Tusc5 transcript levels in the WAT when comparing pre- versus posttreatment matched samples (in arbitrary fluorescence signal units): 3084 ± 564 versus 3017 ± 601 in pre- versus posttreatment, respectively (P > .1).
Neg (no) Gene_expression (levels) of Tusc5 associated with diabetes mellitus and obesity
20) Confidence 0.67 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.63 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox